Here, we report the frequency of ALK fusion in a cohort of 521 Chinese lung cancer patients, and analyze the presence of ALK fusion in relation to clinicopathological characteristics and other driver genes mutations or expression (including SPP1) using whole exome sequencing (WES) and NanoString-based assay. This evidence concerns the gene ALK and lung carcinoma.